TOPIC PAGE NO. - IIPTA · • Hyaluronic acid – Hyasis® ... • Market share in industrial...

1 www.iipta.com

Patent Portfolio Of Novozymes

This report consist the patent portfolio of Novozyme which is an industrial biotechnological organization focusing in enzymes, microbes and

biopharmaceuticals. The main aim of preparing a portfolio of this organization is to give an insight of the current status of the organization.With an aim to give the competitive profile of the organization patent portfolio is the best mode of representation which encompasses both the monetary and the non-monetary domain for the organization and its future planning with regard to the current locus standii.The study and the finding of this report show that the organization underwent a rapid growth due to its focus on the enzyme domain which has huge industrial application in a wide range of industries. This is the major strength of the organization where the company has given its maximum attention and worked on protease and amylase class of enzymes.

ABSTRACT

www.iipta.com 2


TOPIC PAGE NO.

COMPANY OVERVIEW ..........................................................................................1. Company history ..................................................................................................2. Vision & sustainability .........................................................................................3. Important Locations and Subsidiaries ...............................................................4. Key Operational Heads .......................................................................................5. Key Employees .....................................................................................................6. Business description ............................................................................................7. R&D and patents ..................................................................................................8. Major Products and Services ...............................................................................

Biopharmaceuticals ..................................................................................... Enzymes .......................................................................................................

9. Financial Statistics ...............................................................................................10. Sales Report ..........................................................................................................

2011 Sales By geography ............................................................................. 2011 Sales By Industry ................................................................................

11. Key Competitor ....................................................................................................

PATENT SEARCH METHODOLOGY ..................................................................1. Biblographic Data (WIPO) .................................................................................

Applicants Name ..........................................................................................Publication Centre: ......................................................................................Priority Year Graph ......................................................................................Expiry Year Graph ........................................................................................Publication Year Graph ................................................................................IPC Code Graph ..........................................................................................Type of patents ..............................................................................................

2. Technical Data Analysis .......................................................................................Technical Classification ...............................................................................Secondary Classification ..............................................................................• Main Ingredients .....................................................................................• Industrial Applications ...........................................................................• End products ...........................................................................................• Variants ....................................................................................................• Process ......................................................................................................• Pretreatment ............................................................................................• Filling Trend of Main Technology ........................................................• Appendix ..................................................................................................

(i)(ii)(iii)(iv)(v)(vi)(vii)

(i)(ii)

(i)(ii)

(i)(ii)

3 - 633333

3 - 44

4 - 54

4 - 55

5 - 6566

7 - 337 - 178 - 91011

12 - 1314 - 15

1617

18 - 3318 - 1920 - 3320 - 22

232425

26 - 2728 - 2930 - 3132 - 33

TABLE OF CONTENTS

3 www.iipta.com


COMPANY OVERVIEWCompany history:• Novozymes was founded in 2000 in a demerger from pharmaceutical company Novo

Nordisk. Novozymes’ roots date back to the 1920s when Novo Terapeutisk Laboratorium and Nordisk Insulin laboratorium were established in Copenhagen, Denmark. Enzyme production began in 1941.

Vision & sustainability:• Vision is to create the necessary balance between better business, a cleaner environment,

and better lives.• In 2011, the worldwide application of products helped customers reduce their CO2 emissions

by an estimated 45 million tons. It is their ambition to enable a 75 million ton reduction in CO2 emissions in 2015.

Important Locations And Subsidiaries:• Denmark (2,537)• China (1,109)• North America (1,045)• Brazil (248)• India (430)• Europe (274)(April2012)

Key Operational Heads:• Benny Loft, Executive Vice President and CFO• Thomas Nagy, Executive Vice President,• Peder Holk Nielsen, Executive Vice President,• Thomas Videbaek, Executive Vice President, BioBusiness

Key Employes:• Steen Riisgaard, President and CEO• Per Falholt, Executive Vice President, in more than 30 countries

Business description:• Novozymes is the world leader in bioinnovation. Their business is industrial enzymes,

microorganisms, and biopharmaceutical ingredients. Enzymes are the main part of business, currently accounting for 90% of sales. Enzymes are proteins, and in nature they catalyze biochemical reactions in all living organisms.

www.iipta.com 4


• Novozymes finds enzymes in nature and optimize them for use in industry. Enzymes are used in the production of a variety of everyday products. They can turn agricultural waste into biofuel, they replace oil-based chemicals in detergents, and they can keep bread fresh longer.

• In Industry, enzymes replace chemicals and accelerate production processes and help companies make more from less by saving water, energy, raw materials and waste.

R&D and patents:• Around 14% of our revenue is spent on research and development, and currently holds

almost 7,000 patents, which indicates the possibilities when nature and technology join forces

Major Products and Services• Novozymes microbial productsRhizoMyx®,RhizoMyco®, and RhizoPlex®, contain complex

blends of beneficial bacteria,mycorrhizae and bio-stimulant compounds, applied at planting ortransplanting, these products aid in early root establishment,uniform growth, stress resistance, and improved crop health.

• Proventus LC®,Proventus DS®,Proventus SB®are complex blends of bio-stimulant compounds applied throughout vegetativegrowth to help manage crop stress.

Biopharmaceuticals:• Recombinant albumin USP-NF* – Albucult®, Recombumin®• Hyaluronic acid – Hyasis®• Half-life extension (HLE)technology – Albufuse®,Albufuse®Flex, Recombumin®Flex

Enzymes:• Novamyl- Is the widely recognized and market proven solution that maintains . the freshness

of baked products over time.• Dough improvement: Lipopan®, Gluzyme® Mono,Panzea®,Pentopan®• Product Apperance: AMG®, Gold crust.• Flour Modification: Fungamyl®• Biscuits and Snacks: Acrylaway®

5 www.iipta.com


Proteases

AlcalaseAlcalaseUltraEverlaseLiquanaseLiquanaseUltraPolarzymeOvozymeSavinaseSavinaseUltra

DuramylStainzymeStainzymePlusTermamylTermamylUltra

MannawayCarezymeCelluzymeEndolaseCelluclean

Lipolase LipexLipoclean

PectawashXPect

Lipases PectinasesAmylases Cellulase Mannanases

Figure 1

Europe/MEA 36%

Asia Paciffic 19%

North America 35%

Latin America

2011 sales by geography:

35

3619

10

Financial Statistics:• Sales: DKK 10.5 billion (~$1.9 billion) (2011)• EBIT margin: 22.3% (2011)• Market share in industrial enzymes: 47% (2011)• R&D: We spend 14% of our revenue on research and development.• Novozymes holds close to 7,000 granted or pending patents

Sales Reports:

www.iipta.com 6


Figure 2

Microorganism 3 %

Household Care Enzyme 31 %Food & Beverages Enzymes 29 %Bioenergy Enzymes 17%Feed &other Technical Enzymes 13 %Biopharma 7 %

2011 Sales By Industry:

29

31

37

1317

Key Competitor:• Proctor & Gamble• Unilever PLC• Biocon• Dupont• Advanced Enzyme• AB enzyme• Danisco/Genencor• Syngenta

7 www.iipta.com


NAME

0

10

20

30

40

50

60

70

80

Sven

dsen

Alla

n Vind Je

sper

Xu, Fen

g

Andersen

Carsten

Nielsen Per

Munk

Harris P

aul

Schuelein M

artin

Berka R

andy

Daniel

sen,

Steffen

Figure 3

Biblographic Data (WIPO):

Table 2

Svendsen Allan 79

Vind Jesper 26

19

18Andersen Carsten

Xu, Feng

17Nielsen Per Munk

16Harris Paul

15Schuelein Martin

13Steffen

14Berka Randy Danielsen,

NO. OF PATENT

PATENT SEARCH METHODOLOGY

www.iipta.com 8


Applicant’s Name NO. OF Filings

Novozymes A/S 1674

Novozymes Inc 227

Novozymes North America, 169 Novozymes Biotech Inc 59

Novozymes Biopharma 35

Novozymes Adenium Biotech 32

Novozymes Biopolymer 32

Novozymes Biologicals 24

Novozymes Delta Limited 24

Human Genome Sciences 16

Solae Llc 13 Chr Hansen AS 10

Novo Nordisk Biotech, Inc. 5

Solvay Pharmaceuticals 5

DSM IP Assets Bv 3

Applicants Name: The main inventor graph describes the inventor who has filled highest number of patents. Svendsen Allan is the inventor who has filled first patent for Novozymes regarding amylase enzymes

Table 3

9 www.iipta.com


0200400600800

1000

1200

14001600

1800

Novozym

es A/S

Novozymes North

America,

Novozymes Biotec

h Inc

Novozym

es Biopharm

a

Novozym

es Aden

ium

Novozym

es Biopolym

er

Novozymes Biologica

ls

Novozymes Delta

Limited

Human G

enome S

ciences

Solae

Llc

Chr Han

sen A

SNov

o Nord

isk

Solva

y Pharm

aceutic

als

DSM IP

Asse

ts Bv

The highest number of application is filed by the subsidiary Novozymes A/S. The reason being is the subsidiary's engagement mostly in enzyme and protein engineering research which is almost 90%. This is in continuation of the previous graph where the highest number of invention belongs to Svendsen Allan who is involved in enzyme and protein engineering.

Figure 4

www.iipta.com 10


EP 1094

WO 1015

MX 109

KR 89

ZA 34

JP 17

IL 12

SG 11

ES 7

AR 4

0200

400600800

10001200

EP WO MX KR ZA JP IL SG ES AR

The main publication centers are EP and WIPO which is evident from thegraph. This shows that the company's main area of operation is Europe. Also,two of its top inventors Svendsen Allan and Vind Jesper work in the Danishfacility making it reasonable to be filed in Europe. This also suggests that themajor profit to the organization comes from Europe.

Figure 5

Table 4

Publication Centre:

PATENTSCOUNTRY

11 www.iipta.com


Figure 6

Table 5

0

10050

150200250300

350400450

500

1998 1999 2001 2002 2003 2004 2006 2007 2008 2009

The graph shows that there had been growth in research in the 1990s. This is the reason for the steady growth in filing; which is ultimately also the priority date (year). This could also be because of the research is mainly in the enzyme and protein engineering which has huge industrial application; which coincides the filing and priority date of the inventions.

Priority Year Graph:

1998 122

1999 113

2001 155

2002 466

2003 163

2004 176

2006 120

2007 176

2008 169

2009 148

YEAR PATENTS

www.iipta.com 12


2006 32008 42009 52010 12011 42012 132013 202014 342015 532016 582017 952018 1222019 1132020 582021 1552022 4662023 1632024 1762025 892026 1202027 1762028 1692029 1482030 1082031 42

Table 6

Expiry Year Graph:

NO OF PATENTEXPIRY DATE

13 www.iipta.com


0

10050

150200250300

350

400450

500

2006

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Figure 7The expiry dates of the patents are in relation to the filing/priority dates of the patent. Here, most of the patents expire in the 2020s. This shows that the most of the company's patent will be free to use thereafter. Thus, in order to continue its monopoly in the market the organisation needs to focus on the improvement of those technologies.

www.iipta.com 14


Table 7

Publication Year Graph:

2012 1682011 2642010 2642009 1692008 1232007 782006 1982055 1842004 1332003 1222002 1592001 2122000 1371999 471998 471997 311996 251995 151994 11993 21992 21991 31990 11989 11988 51987 11986 2

PATENTSPUBLICATION DATES

15 www.iipta.com


0

100

50

150

200

250

300

2012

20

11

2010

20

09

2008

2007

20

06

2055

20

04

2003

20

02

2001

20

00

1999

19

98

1997

19

96

1995

19

94

1993

19

92

1991

19

90

1989

19

88

1987

19

86

Figure 8The graph shows a gradual and rapid increase in the in the publication in themiddle of 1990s. This is again in coincidence with the priority year which also suggests the same interpretation. Thus, the organisation made a rapid stride in technological edge in the next decade i.e. 2000s due to its rapid research work in the previous decade.

www.iipta.com 16


IPC Code Graph:

0

200

600800

1000

1200

1400

C12N C11D C07K C12N A61K A21D A23K A23CA23L A23K D06M

Table 8

Figure 9The patents mainly belongs to C12 class which represents Chemistry as the main class and further subdivided as C12N which is of Micro-organism or Enzymes. This represents that the companies’ main area of focus isMicro-organism Or Enzymes.

A21D 79A23C 59A23K 51A23L 60A61K 94C07K 207C11D 212C12N 999C12P 190D06M 31

No. of PatentIPC

17 www.iipta.com


Table 9

Figure 10

Type of patents:

TYPES NO.OF PATENTS

Process 860Product 694Product & Process 40

0

200

400

600

800

1000

Process Product Product & Process

The graph suggests that the organisation has almost equal number of patents in all the three existing class. Also, there is a scope to convert process and product patent to process & product patent for a strong protection.

www.iipta.com 18


Technical Data Analysis:Technical Classification:

Primary Classification

Indusrial Application

Enhance/Promoters

Pretreatment

Variants

End Product

Process

Main Ingredient

Other Ingredient

The map shows that different classes which has been divided into secondary class and discussed thoroughly in coming pages.

Figure 11

19 www.iipta.com


Technical Classification:

The graph suggests that the organisation's research mainly focuses on the main ingredients where enzyme has a major role to play. Also, it has secured the protection where the invention (patented product, process or both) isused as a main ingredient making it a major revenue generator.

0

500

1000

1500

2000

2500

Main ingred

ients

Other ingredients

Industrial Applications

End Products

Variants

Process

Pretrea

tment

Enhancer/Promoter

Table 10

Figure 12

Main ingredients 2045Other ingredients 1860Industrial Applications 1634End Products 758Variants 689Process 499Pretreatment 256Enhancer/Promoter 54

PatentsTitle

www.iipta.com 20


Secondary Classification:

Main Ingredients:

0

200400

600

800

1000

2000

Enzymes Polypeptide Acids Proteins Dna Microorganisms

The graph suggests that the company mainly focuses on enzymes because of its huge sales volume and the top applicants have enzyme as their mainarea of expertise.

Figure 13

Table 11

Enzymes 1106Polypeptide 439Acids 217Proteins 123Dna 96Microorganisms 64

PATENTSTOPIC

21 www.iipta.com


Table 12

Nucleic Acid Constructs 440 Host cells 432 Vector 392 Enzyme compositions 167 Isolatedpolynucleotides 128 Cellulosic materials 71 Micro-organisms 46 Polypeptides 32 Markers 27 Cloned genes 21 Enzymes 18 Gene Library 18 Catalase 13Enhancer Agents 12Antibody Binding Peptide Sequence 10Enzyme stabilizers 10Sulphurcontaining compounds 6Organic compounds 5DNA templates and primers 4Nitrogen containing compounds 3Nucleic acid probes 2Divalent copper cations 1Dioxy compound 1Bicycliccompound 1

Ingredient Patents

www.iipta.com 22


0

50

150

200

250

300

350

400

450

500

Nuc

leic

Aci

d C

onst

ruct

s

Hos

t cel

lsVe

ctor

Enzy

me

com

posit

ions

Isol

ated

poly

nucl

eotid

es

Cel

lulo

sic m

ater

ials

Mic

ro-o

rgan

isms

Poly

pept

ides

Mar

kers

Clo

ned

gene

sEn

zym

es

Gen

e Li

brar

y

Cat

alas

eEn

hanc

er A

gent

sA

ntib

ody

Bind

ing

Enzy

me

stab

ilize

rs

Org

anic

com

poun

ds

DN

A te

mpl

ates

Nitr

ogen

cont

aini

ng...

Nuc

leic

aci

d pr

obes

Div

alen

t cop

per c

atio

nsD

ioxy

com

poun

d

Bicy

clic

com

poun

d

Figure 14

Although the company’s main focus is on enzymes but this graph shows other ingredients being greatly used which gives us the idea that company has used the enzymes in different technology so that the main technology can be nested and can be easily protected.

23 www.iipta.com


Figure 15

Table 13

Industrial Applications:

0

100

200

300

400

500600

700800

Bioc

hem

ical

s

Pha

rmac

eutic

als

Oth

ers

A

nim

al fe

ed

Dai

ry p

rodu

cts

Fe

rmen

tatio

n

fo

od p

rodu

cts

B

rew

erie

s

This graph shows that the organisation is seriously involved in the high tech industrial application. It is evident that the main area of focus being the biochemical and the pharmaceutical sector which has enzymatic application inproduction

Biochemicals PharmaceuticalsOthers 369Animal feed products Dairy products FermentationFood products Breweries

PatentsUse678385369270208200176108

www.iipta.com 24


Table 14

0

50

150

200

250

Fermented

Products

Milk Products

Beverages

Micro-organism

s

Bio-chem

icals

Baked products

Enzymes

Feed

The patent here mainly involves fermented and milk products and the beverages. This has a correlation with data from fig. 2 where 29% of sales volume is generated from food and beverage enzyme which is overall the food sector.

Figure 16

End products:

Fermented Products 20Milk Products 188Beverages 135Micro-organisms 68Bio-chemicals 62Baked products 53Enzymes 26Feed 18

PatentsEnd Product

25 www.iipta.com


Table 15

Figure 17

0

50

150

200

250

300

350

400450

Poly-peptides

Poly-nucleotid

es

DNA sequence

Albumin

Amylase v

ariants

Protease

varian

ts

Lipase va

riants

Glycoam

ylase

sequen

ce

Variants:

Poly-peptides 388Poly-nucleotides 83DNA sequence 70Albumin 48Amylase variants 40Protease variants 31Lipase variants 25Glycoamylase sequence 4

No. of PatentsVariants

www.iipta.com 26


Table 16

Process:

Production 256Fermentation 71Degradation 37Treatment 29Control 24Manufacture 18Cleaning 13Reduction 11Purification 9Processing 7Saccharification 4Bleaching 3Inactivation 3Screening 3Disinfection 2Filtration 2Separation 2Solubility 2Dyeing 1Steeping 1Tanning 1

NO OF PATENTPROCESS

27 www.iipta.com


This graph suggests that the protection of the organisation (whether process, product or both) mainly focuses on the production aspect. This production is involved in a wide range of operation which can be seen through other depicted graphs.

0

50

100

150

200

250

300

Production

Fermentation

Degradation

Treatment

Control

Manufacture

Cleaning

Reduction

Purificat

ion

Processin

g

Sacchari

fication

Bleach

ingIn

activ

ation

Scree

ningDisi

nfectio

nFil

tratio

nSe

parat

ionSo

lubilit

y

Dyein

gSte

epin

gTa

nnin

g

Figure 18

www.iipta.com 28


40

0

80

120

160

200

Food treatment Recycling

Pretreatment:

Enzyme is used in the process of pre-treatment where treatment of food products is the main focus which correlates with fig. 2 where major contribution in salesvolume is by food and beverages.

Figure 19

Table 17

Detoxification

Food Treatment 170Recycling 48Detoxification 38

Pre-treatment Patents

29 www.iipta.com


Figure 20

Table 18

0

5

10

15

20

25

30

35

40

Cellulotic properties

Amylolytic properties

Reducing amino acids

Reduction of malodour

Reducing biofilm

Enhancingwaterability

Flavour enhancing

Reduction in gene expression

Cellulotic properties 34Amylolytic properties 7Reducing amino acids 4Reduction ofmalodour 3Reducing biofilm 2Enhancingwaterability 2Flavour enhancing 1Reduction in gene expression 1

Enhancer No. of Patents

www.iipta.com 30


Filing Trend of Main Technology:As the Enzymes are the main technology which can be easily be seen through the graph of filling trends of Novozymes.

Table 19

Year2011 122010 422009 722008 732007 612006 482005 352004 722003 752002 1962001 702000 311999 621998 781997 571996 291995 381994 151993 181992 131991 31990 11989 41988 1

Patents

31 www.iipta.com


After studying the portfolio of Novozymes and the graphs analysed we have interpreted that, company mainly focuses on the enzymes which is theirmain technology. Furthermore, the company was highest filler in the year2002 while in the subsequent years the trend of filling has declined till date.Market trends: The Company basically focuses on filling the patents inEuropean Union which concludes that the main focusing area is Europe.

Figure 21

0

50

100

150

200

250

2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988

www.iipta.com 32


1

2

3

4

S.NO

Microorganisms

Acids2

Proteins

Enzymes

PRIMARY

77

92

175

551

PATENTS

Bacteria Algae Yeast Fungi Virus

Hyaluronic AcidAlpha Hydroxy AcidAryl Carboxylic Acid

HydroxypropionicAcid

Acrylic AcidFatty Acid

Phytic AcidChitin BindingProteins

AlbuminTransferrin

HeterologousProtein

L12HomologousProtein

FusionProteinRecombinant

ProteinPyrophosphatase

EnzymesAmylase

Alpha-AmylaseLipolyticDfpaseHybridLipase

SECONDARY

313

12292

3443

23

4422

443

295

1537

40

2

15510675

1366

PATENTS

33 www.iipta.com


S.NO PRIMARY PATENTS

Protease Subtilase Nuclease Phytase

Dehydrgenase Endoglucanase

SECONDARY

87972

352

10

PATENTS

EndoglucanaseActivity

Cellulolytic Enhancing Activity

HeterologousPolypeptides

GlucoamylaseActivity

Lipolytic ActivityXylanase ActivityCellobiohydrolase

ActivityIsoamylase ActivityBeta-Glucosidase

ActivityLysophospholipase

Activity Endopeptidase

ActivityAntimicrobial

ActivityHaloperoxidase

Activity Nucleic Acid

EncodingPolypeptide

5

6

Polypeptide

DNA

204

83

20

55

5

14

314

26

2

13

2

2

40

8

65

TOPIC PAGE NO. - IIPTA · • Hyaluronic acid – Hyasis® ... • Market share in industrial...

Documents

Transcript of TOPIC PAGE NO. - IIPTA · • Hyaluronic acid – Hyasis® ... • Market share in industrial...